Evidence map›Paper›PMID 21655106›Full record

ReviewPLoS pathogens2011

Structural and mechanistic studies of measles virus illuminate paramyxovirus entry.

Richard K Plemper, Melinda A Brindley, Ronald M Iorio

Open access · goldAbstract readReview
In one paragraph

Review in PLoS pathogens, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. A universal design of restructured dimer antigens: Development of a superior vaccine against the paramyxovirus in transgenic rice.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  7. Article
  8. Virus-Associated Nephropathies: A Narrative Review.International journal of molecular sciences · 2022
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. WeakJournal of virology · 2020
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Structures of the prefusion form of measles virus fusion protein in complex with inhibitors.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Richard K PlemperDepartment of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, United States of America. rplempe@emory.edu
Melinda A Brindley
Ronald M Iorio
Emory University · USUniversity of Massachusetts Chan Medical School · US

Funding

Technologies for Human Cellular ImmunologyU19AI057319 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI FINBERG, ROBERT WILLIAM · 2003 to 2013
$34.4M
Identification and Pre-Clinical Evaluation of Measles Virus InhibitorsR01AI071002 · NIAID · GEORGIA STATE UNIVERSITY · PI PLEMPER, RICHARD K. · 2006 to 2022
$6.6M
Glycoprotein interactions in paramyxovirus fusionR01AI049268 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI IORIO, RONALD M · 2001 to 2011
$3.6M
Cryo-Electron and Biochemical Anaysis of Native Paramyxovirus Fusion ComplexesR01AI083402 · NIAID · GEORGIA STATE UNIVERSITY · PI PLEMPER, RICHARD K. · 2011 to 2015
$1.7M
Glycoprotein interactions in paramyxovirus fusionR56AI049268 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI IORIO, RONALD M · 2006 to 2006
$402k
Cryo-Electron and Biochemical Analysis of Native Paramyxovirus Fusion ComplexesR56AI083402 · NIAID · EMORY UNIVERSITY · PI PLEMPER, RICHARD K. · 2010 to 2010
$380k
Structural and biochemical characterization of paramyxovirus fusion complexesF32AI085763 · NIAID · EMORY UNIVERSITY · PI BRINDLEY, MELINDA ANN · 2010 to 2010
$50k
NIAID NIH HHS AI057319NIAID NIH HHS AI071002NIAID NIH HHS AI083402NIAID NIH HHS AI085763NIAID NIH HHS AI49268NIAID NIH HHS F32 AI085763NIAID NIH HHS R01 AI049268NIAID NIH HHS R01 AI071002NIAID NIH HHS R01 AI083402NIAID NIH HHS R56 AI049268NIAID NIH HHS R56 AI083402NIAID NIH HHS U19 AI057319
6 · The paper itself

Abstract

Measles virus (MeV), a member of the paramyxovirus family of enveloped RNA viruses and one of the most infectious viral pathogens identified, accounts for major pediatric morbidity and mortality worldwide although coordinated efforts to achieve global measles control are in place. Target cell entry is mediated by two viral envelope glycoproteins, the attachment (H) and fusion (F) proteins, which form a complex that achieves merger of the envelope with target cell membranes. Despite continually expanding knowledge of the entry strategies employed by enveloped viruses, our molecular insight into the organization of functional paramyxovirus fusion complexes and the mechanisms by which the receptor binding by the attachment protein triggers the required conformational rearrangements of the fusion protein remain incomplete. Recently reported crystal structures of the MeV attachment protein in complex with its cellular receptors CD46 or SLAM and newly developed functional assays have now illuminated some of the fundamental principles that govern cell entry by this archetype member of the paramyxovirus family. Here, we review these advances in our molecular understanding of MeV entry in the context of diverse entry strategies employed by other members of the paramyxovirus family.

Indexed as

Virus InternalizationCell MembraneChildHumansMeaslesMeasles virusMembrane FusionParamyxovirinaeReceptors, VirusViral Fusion ProteinsVirus AttachmentReceptors, VirusViral Fusion Proteins

Identifiers

PMID21655106
PMCPMC3107210
OpenAlexW2046563809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.